Results 1 to 10 of about 35,719 (245)

Mechanisms of Action and Limitations of Monoclonal Antibodies and Single Chain Fragment Variable (scFv) in the Treatment of Cancer

open access: yesBiomedicines, 2023
Monoclonal antibodies are among the most effective tools for detecting tumor-associated antigens. The U.S. Food and Drug Administration (FDA) has approved more than 36 therapeutic antibodies for developing novel alternative therapies that have ...
Berenice Illades-Aguiar   +2 more
exaly   +2 more sources

“Stapling” scFv for multispecific biotherapeutics of superior properties

open access: yesmAbs, 2023
Single-chain fragment variable (scFv) domains play an important role in antibody-based therapeutic modalities, such as bispecifics, multispecifics and chimeric antigen receptor T cells or natural killer cells.
Lauren E. Boucher   +29 more
doaj   +2 more sources

Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells

open access: yesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2020
A targeted nanomedicine with humanized anti-EGFR scFv (NM-scFv) was developed for siRNA delivery into triple negative breast cancer (TNBC) cells. NM-scFv consisted of i) targeted nanovector (NV-scFv): nano-cargo with targeting properties; ii) siRNA ...
Phuoc-Vinh Nguyen   +2 more
exaly   +2 more sources

Complementarity determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv. [PDF]

open access: yesPLoS ONE, 2017
CyDisCo is a system facilitating disulfide bond formation in recombinant proteins in the cytoplasm of Escherichia coli. Previously we screened for soluble expression of single chain antibody fragments (scFv) in the cytoplasm of E.
Anna Gąciarz, Lloyd W Ruddock
doaj   +2 more sources

Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity

open access: yesJournal of Nanobiotechnology, 2021
Background Tumor-targeted nanoparticles hold great promise as new tools for therapy of liquid cancers. Furthermore, the therapeutic efficacy of nanoparticles can be improved by enhancing the cancer cellular internalization.
Kai-Wen Ho   +13 more
doaj   +2 more sources

A novel synthetic trivalent single chain variable fragment (tri-scFv) construction platform based on the SpyTag/SpyCatcher protein ligase system

open access: yesBMC Biotechnology, 2018
Background Advances in antibody engineering provide strategies to construct recombinant antibody-like molecules with modified pharmacokinetic properties.
Md. Kausar Alam   +5 more
doaj   +2 more sources

Development of a recombinant biosimilar single-chain variable fragment antibody targeting human estrogen receptor α36 [PDF]

open access: yesResearch in Pharmaceutical Sciences
Background and purpose: The estrogen receptor alpha-36 (ER-α36) is an alternative splice variant of classical ER-α66 and is abundantly present in both ER-α66-positive and ER-α66-negative breast tumor cells.
Soodabeh Shafiee   +7 more
doaj   +2 more sources

Screening of a ScFv Antibody With High Affinity for Application in Human IFN-γ Immunoassay

open access: yesFrontiers in Microbiology, 2018
Interferon gamma (IFN-γ), a signal proinflammatory cytokine secreted by immune cell, and plays a critical role in the pathogenesis and progression of many diseases.
Qinghong Zhang   +2 more
exaly   +2 more sources

Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp

open access: yesFrontiers in Cellular and Infection Microbiology, 2013
Single-chain variable fragment (scFv) is a class of engineered antibodies generated by the fusion of the heavy (VH) and light chains (VL) of immunoglobulins through a short polypeptide linker.
Rongzhi Wang   +2 more
exaly   +3 more sources

Development of a single-chain fragment variable fused-mutant HALT-1 recombinant immunotoxin against G12V mutated KRAS colorectal cancer cells [PDF]

open access: yesPeerJ, 2021
Background KRAS oncogenes harboring codon G12 and G13 substitutions are considered gatekeeper mutations which drive oncogenesis in many cancers.
Michelle Yee Mun Teo   +6 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy